Suchen
Nektar Therapeutics
NKTRZur Watchlist hinzufügen
68.730USD
+0.370+0.54%
Trading geöffnet 09/18, 13:23（ET）
2.35BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Nektar Therapeutics Unternehmen
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Nektar Therapeutics Profil
BörsenkürzelNKTR
Name des UnternehmensNektar Therapeutics
IPO-datumMay 03, 1994
CEORobin (Howard W)
Anzahl der mitarbeiter61
WertpapierartOrdinary Share
GeschäftsjahresendeMay 03
Addresse455 Mission Bay Boulevard South
StadtSAN FRANCISCO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94158
Telefon18554826587
Websitehttps://www.nektar.com/
BörsenkürzelNKTR
IPO-datumMay 03, 1994
CEORobin (Howard W)
Führungskräfte von Nektar Therapeutics
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.70K
-1.17%
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.70K
-1.17%
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.70K
-1.17%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
4.10K
-4.54%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
4.10K
-4.54%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
4.10K
-4.54%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.70K
-1.17%
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.70K
-1.17%
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.70K
-1.17%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
4.10K
-4.54%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
4.10K
-4.54%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
4.10K
-4.54%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Nektar Therapeutics?
Die fünf größten Anteilseigner von Nektar Therapeutics sind: Mr. Howard W. Robin
Wie viele Institutionen halten Anteile an Nektar Therapeutics (NKTR)?
Mit Stand vom 2026Q1 halten 437 Institutionen Anteile an Nektar Therapeutics, mit einem Gesamtmarktwert von etwa 20.71M, was 61.39% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 1322059.00 gestiegen.